cells failed to induce MyHC IIb expression to the same level as in wild-type cells and showed reduced myotube formation. Supplementation of IL-6 could partially restore the fusion of IL-6 Ϫ/Ϫ cells. These data demonstrate that IL-6 depletion during myogenic differentiation does not reduce the activation of the STAT3-Socs3 cascade, while IL-6 and STAT3 are both necessary to promote myotube fusion.
Socs3; STAT3; differentiation; IGF-I; IL-6
Ϫ/Ϫ myoblasts (IL-6) IS CLASSICALLY known as a central player in the regulation of inflammation, hematopoesis, immune response, and host defense mechanisms. During the last decade, IL-6 has also been recognized as being a myokine (20) , with the working skeletal muscle as predominant producer of IL-6 during exercise (9, 25) . While strenuous physical activity can be accompanied by an up to 100-fold increase of plasma IL-6 (19, 21), short-term moderate intensity exercise leads to high interstitial IL-6 concentrations within the muscle without a significant rise in circulating levels (22) . This implies that skeletal muscle per se is an important target for IL-6. Subsequent studies in human and rat L6 myotubes, in human muscle strips, and in rodent muscle demonstrate that IL-6 may promote fuel uptake and utilization by the working muscle (1, 4, 5, 7, 34) . Studies in IL-6-deficient mice show impaired recovery of their muscle mass from atrophy (33) , and a detailed investigation of these mice could provide evidence that muscle-produced IL-6 regulates muscle growth in vivo due to impaired proliferation and migration of satellite cells (23) . IL-6 is also implicated in the activation and proliferation of human muscle satellite cells following eccentric muscle contractions (15, 28) . Thus there is good evidence that IL-6 is important for skeletal muscle hypertrophy. Whether IL-6 also regulates the differentiation and fusion of skeletal muscle cells is less clear. Stimulation of C2C12 myoblasts with recombinant IL-6 induces the expression of the transcription factor myogenin, an important initiator of the differentiation program (3) . In contrast, other members of the IL-6 family, namely leukemia inhibitory factor (LIF; Refs. 2, 11) and cardiotrophin-1 (CT-1; Ref. 17) , have been reported to inhibit myogenic differentiation in skeletal muscle cells. The signal transduction induced by IL-6 and its related cytokines is mediated by homo-or heterodimerization of the gp130 receptor, subsequent activation of Janus kinases (JAK), and phosphorylation of signal transducers and activators of transcription (STAT) (8) . Studies in C2C12 cells and mouse primary myoblasts showed that a JAK1/STAT1 pathway promotes proliferation and prevents differentiation (26) , while a JAK2/ STAT2/STAT3 pathway is required for myogenic differentiation (31) . A recent publication of the same group added more details to this field: activation of the negative feedback regulators suppressor of cytokine signaling (Socs)1, Socs3, and protein inhibitor of activated STAT (PIAS)1 downregulates the JAK1/STAT1/STAT3 pathway, an event apparently essential for myogenic differentiation (6) . Notably, overexpression of Socs3 has been shown to induce myoblast differentiation (24) . The specific function of STAT3 in the differentiation program of skeletal muscle cells remains unclear, since STAT3 activity could be necessary for the induction of Socs3, while on the other hand STAT3 can directly interact with and inhibit the activity of the muscle-specific transcription factor MyoD, which plays an essential role in differentiation (12) . Furthermore, it is unknown whether IL-6 as an activator of STAT3 and subsequent Socs3 expression is necessary for the differentiation and fusion of skeletal muscle cells.
In conclusion, there is good evidence from previous studies that components of the IL-6-STAT3-Socs3 signaling cascade are regulators of myogenic differentiation, but the function of endogenous IL-6 production in muscle cells herein is unknown.
We focused here on the importance of IL-6 and its downstream signaling molecules STAT3 and Socs3 in the differentiation of C2C12 muscle cells and of primary mouse muscle cells. We demonstrate that activation of STAT3 and Socs3 is an early, but IL-6-independent, event that induces the myogenic differentiation program, while lack of IL-6 also impairs myotube fusion.
EXPERIMENTAL PROCEDURES
Materials. LightCycler system was from Roche (Mannheim, Germany). Oligonucleotides were from Qiagen (Hilden, Germany) or synthesized by Invitrogen (Karlsruhe, Germany). Antibodies against phospho-STAT3 (no. 9131), STAT3 (no. 9132), and ␤-actin (no. 4970) were from Cell Signaling (Frankfurt, Germany), and the protease inhibitor mixture was from Roche. IL-6 (mouse, recombinant protein) was from R&D Systems (Wiesbaden-Nordenstadt, Germany).
Cell culture. C2C12 myoblasts were obtained from ATCC and cultured in growth medium (DMEM; Lonza) containing 25 mM glucose, 2 mM glutamine, and 1% penicillin/streptomycin and supplemented with 10% FBS (GIBCO). Cells were seeded in a density of 1 ϫ 10 5 cells/well of a six-well dish. Myotube formation was induced after 48 h by switch to fusion medium (FM) consisting of DMEM containing 25 mM glucose and 2% FBS. Medium was replaced every other day.
The mouse studies experiments were conducted in accordance with the national guidelines of laboratory animal care and were approved by the local governmental commission for animal research (Regierungspraesidium Tuebingen, Baden-Wuerttemberg, Germany). Primary mouse myoblasts were isolated according to a method described for rat myoblasts (13) . Briefly, C57/Bl6 mice and IL-6 Ϫ/Ϫ (B6.129S2-Il6 tmlKopf /J) maintained on a C57Bl/6J-background (purchased from Jackson Laboratory, Bar Harbor, ME) were anesthetized with an intraperitoneal injection of ketamine (150 mg/kg body wt) and xylazine (10 mg/kg body wt) and killed by decapitation. Quadriceps muscles were dissected out and placed in ice-cold Dulbecco's PBS containing 1% glucose and 0.5% penicillin/streptomycin. Muscles were carefully minced and rotated in DMEM containing 25 mM glucose, 1% penicillin/streptomycin, and 0.2% collagenase (CLS, Worthington) for 90 min at 37°C. After centrifugation at 300 g for 15 min, the pellet was resuspended in DMEM containing 25 mM glucose, 1% penicillin/streptomycin, 0.2% collagenase, and 0.25% trypsin and rotated for 30 min at 37°C. The cell suspension was diluted with primary growth medium [PGM; DMEM with 25 mM glucose, 10% horse serum (GIBCO), 10% FBS, 2 mM glutamine and 1% penicillin/streptomycin], centrifugated for 15 min at 300 g, resuspended in PGM and filtered through a 70-m sterile filter. Equal number of cells were seeded onto dishes precoated with Matrigel (no. 356234; Becton-Dickinson) in a 1:6 dilution with DMEM. Medium was replaced every other day. Primary mouse myoblasts started spontaneously to differentiate in PGM and FM which was set as day 0 of differentiation. Sufficient myotube maturation was only observed in PGM but not in serum-reduced DMEM. C2C12 myoblasts also differentiate in PGM with no obvious difference in the number of fused myotubes, but a defined start of differentiation could only be achieved by switching from growth medium containing 10% FBS to the serum reduced FM.
RNA isolation and quantitative PCR analysis. RNA was extracted with the RNeasy kit (Qiagen) according to the manufacturer's instructions. Reverse transcription of total RNA (1 g) was performed in a volume of 20 l using random hexamer primers with the first strand cDNA synthesis kit for RT-PCR (Roche, Mannheim, Germany). Aliquots (2 l) of the reverse transcription reactions were then submitted to online quantitative PCR with the Light Cycler system (Roche) with SYBR green using FastStart DNA-MasterSYBR Green I (Roche) or the QuantiFast SYBR Green PCR kit (Qiagen). The following primer pairs were used: IL-6 sense: gat gct acc aaa ctg gat ata atc, antisense: ggt cct tag cca ctc ctt ctg tg, product of 268 bp; myogenin sense: act ccc tta cgt cca tcg tg, antisense: cag gac agc ccc act taa aa, product of 174 bp; MyHC IIb sense: agc ttg aaa acg agg tgg aa, antisense: cct cct cag cct gtc tct tg, product of 191 bp; Socs3 sense: gct ggc caa aga aat aac ca, antisense: agc tca cca gcc tca tct gt, product of 224 bp; and ␤-actin sense: agc cat gta cgt agc cat cc, antisense: ctc tca gct gtg gtg gtg aa, product of 227 bp. The quantitative PCR was performed in a volume of 20 l: 2 l FastStart DNA-MasterSYBR Green I, 4 mmol/l MgCl 2, and primers at a concentration of 1 mol/l. The instrument settings were: After denaturing at 95°C for 10 min, 50 cycles were performed by denaturing at 95°C for 15 s, annealing at 65°C for 5 s, elongation for 11 s for IL-6; annealing at 64°C for 10 s, elongation for 8 s for myogenin; annealing at 66°C for 10 s, elongation for 15 s for MyHC IIb; annealing at 66°C for 10 s, elongation for 9 s for mouse Socs3; annealing at 69°C for 10 s, elongation for 10 s for mouse ␤-actin. Primers for STAT3: Mm Stat3_1_SG and insulinlike growth factor-I (IGF-I): Mm_Igf1_2_SG were from Qiagen, and instrument settings were as indicated by the manufacturer.
Small interfering RNA. Small interfering (si)RNA targeting IL-6 and STAT3 were designed and synthesized and annealed at Dharmacon Research. An unrelated siRNA targeting firefly luciferase was used as control in all experiments. Transfection was performed with CellPhect (Amersham Biosciences, Buckinghamshere, England) with 200 nM siRNA according to the instructions of the manufacturer. Briefly, 1 ϫ 10 5 cells/well were seeded in six-well plates and transfected in DMEM containing 25 mM glucose and 10% FCS without antibiotics followed by glycerol shock after 24 h. Cells received growth medium or differentiation medium afterwards for the indicated time points.
Tissue lysates and Western blotting. Proteins were separated by 7.5% SDS-PAGE, and Western blotting was performed as previously described (34) . Subcellular fractionation to obtain cytoplasmic and nuclear proteins was performed according to Wang et al. (32) .
Immunostaining. Primary mouse myoblasts were seeded on glass coverslips coated with Matrigel (diluted 1:10 in DMEM) and cultured in PGM as described above until day 10 of differentiation. Cells on coverslips were washed twice in PBS, fixed in PBS containing 4% formaldehyde (pH 7.4) for 20 min, and quenched with 150 mM glycine in PBS for 10 min before being washed again with PBS. Blocking was performed in 5% normal goat serum and 0.05% Tween 20 in PBS for 30 min. Coverslips were incubated with antibody recognizing fast-type skeletal myosin MyHC II (M4276; SigmaAldrich, Deisenhofen, Germany) in blocking solution for 2 h at room temperature, washed three times in PBS and incubated with the Alexa 488-labeled secondary antibody (Invitrogen) in blocking solution for another 1 h and washed again. Nuclei were stained using TO-PRO3 (Invitrogen) diluted 1:1,000 in PBS for 10 min before mounting in Mowiol 4-88 (Calbiochem, Bad Soden, Germany).
Statistical analysis. Data were calculated as means Ϯ SE, and groups of data were compared using Student's t-test. Statistical significance was set at P Ͻ 0.05.
RESULTS
Enhanced expression and secretion of IL-6 in differentiating C2C12 cells. C2C12 skeletal muscle cells are a well-established cell culture system to study the regulation of myotube formation (3, 17, 18, 31) . Myogenic differentiation is induced in these cells by replacing the growth medium containing 10% serum with a serum-reduced medium. First, we studied the regulation of IL-6 mRNA expression during differentiation and compared it with the mRNA expression of the muscle differentiation marker myogenin and myosin heavy chain MyH4, also known as fast MyHC IIb. Figure 1 shows the characteristic 1A ) and a subsequent increase in MyHC IIb expression with the highest expression on day 6 (Ͼ7,000-fold induction; Fig.  1B ). The mRNA expression of IL-6 was first significantly increased on day 3 (2.8-fold) and reached a maximum induction on day 5 (9.1-fold; Fig. 1C ). This upregulation of IL-6 expression led to accumulation of IL-6 protein in the supernatant of the cells, 5.5 Ϯ 0.2 pg/ml on day 3 and 21.3 Ϯ 3.9 pg/ml on day 6 vs. 3.3 Ϯ 0.2 pg/ml on day 1 (Fig. 1C) . After the first 48 h in the differentiation medium, no increases in IL-6 mRNA expression or protein were detected. Of note, the IL-6 target gene Socs3 was significantly induced on day 1 with no further increases during the differentiation process (Fig. 1D) . Thus Socs3 and IL-6 showed divergent expression kinetics in differentiating C2C12 myocytes.
Activation of STAT3 in differentiating C2C12 cells. Next, we investigated the activation of the signal transducer of IL-6, STAT3 in the early differentiation state. Phosphorylation of STAT3 on tyrosine 705 was detected after 6 h in differentiation medium ( Fig. 2A) , and STAT3 remained phosphorylated after 24 and 48 h (Fig. 2B) . The phosphorylated form was only found in the nuclear extracts of the cells, further indicating a very rapid activation and nuclear translocation of STAT3 in myogenic conditions. The observed slight increase in STAT3 protein levels after 24 h in Fig. 2A was accompanied by a significant increase in STAT3 mRNA expression in differentiating cells (Fig. 2C) .
Knockdown of STAT3 blocks differentiation. Activation of STAT3 was confirmed to be responsible for the increased mRNA expression levels of Socs3 during the differentiation process. Silencing STAT3 mRNA by transfecting the cells with siRNA oligonucleotides targeting STAT3 blocked Socs3 induction completely (Fig. 3A) . Moreover, the mRNA levels of myogenin were strongly reduced on days 1, 2, and 3 of differentiation (Fig. 3B) . Subsequently, the induction of MyHC IIb expression was blocked (Fig. 3C ). These data clearly indicate that the early activation of STAT3 is important for the initiation of myotube formation in C2C12 cells.
Knockdown of IL-6 reduces differentiation but does not block phosphorylation of STAT3. The next question was whether IL-6 is responsible for the activation of STAT3 and thus gives the starting signal for the myogenic program. A knockdown approach targeting IL-6 mRNA resulted in a clear reduction of IL-6 mRNA levels during the differentiation process (Fig. 4A) . The C2C12 cells with silenced IL-6 expression also showed reduced myogenin expression on day 2 and reduced MyHC IIb expression on days 2, 4, and 6 of differentiation (Fig. 4, B and C) . Myogenin protein expression levels were decreased by the knockdown of STAT3 and IL-6 on day 2 of differentiation ( Fig. 4D) . On day 7 of differentiation, myotube fusion was detected as number of MyHC II-positive cells (Fig. 4E) . Knockdown of STAT3 resulted in a strong reduction of myotube fusion (fusion index of cells with silenced STAT3 expression was 15 Ϯ 4% of control cells). The effect in C2C12 cells with silenced IL-6 expression was less pronounced but clearly visible (fusion index was 53 Ϯ 20% of control cells). Noteably, knockdown of IL-6 did not prevent the phosphorylation of STAT3 after 24 h in differentiation medium (Fig. 4F) . These data indicate that the early activation of STAT3 is independent of IL-6.
Differentiation of IL-6-deficient mouse primary myoblasts is impaired.
To clarify the importance of endogenous IL-6 production for the myogenic differentiation, primary mouse skeletal muscle cells obtained from quadriceps muscle of wild-type and IL-6-deficient mice were used. Compared with C2C12 cells, primary wild-type cells produced large amounts of IL-6 protein with no further increase during differentiation (Fig. 5A) Ϫ/Ϫ cells (Fig. 5B) . No reduction in the phosphorylation of STAT3 on tyrosine 705 was observed in IL-6 Ϫ/Ϫ cells (Fig. 5C) . Moreover, the increase in STAT3 mRNA expression was not prevented in the IL-6 Ϫ/Ϫ cells (Fig.  5D) . The mRNA expression of Socs3 was slightly reduced on days 0 and 1 in IL-6 Ϫ/Ϫ cells, but not different in later stages of cell differentiation (Fig. 5E ). In contrast, the induction of MyHC IIb mRNA expression was impaired in IL-6 Ϫ/Ϫ cells on day 6 of differentiation ( Fig. 5F ). This effect was clearly visible in IL-6 Ϫ/Ϫ cells on day 10 of differentiation after immunostaining for MyHC II protein. Ϫ/Ϫ cells showed a pronounced reduction in the number of MyHC II-positive cells indicating impairment to form myotubes (Fig. 5, G and H) . Determination of IGF-I expression revealed a strong upregulation during differentiation independent of the genotype (Fig.  5I) . In quadriceps, plantaris, and tibialis muscle of adult wildtype and IL-6 Ϫ/Ϫ mice, MyHC IIb mRNA expression was comparable (Fig. 5J) .
Supplementation of IL-6 partially restores differentiation of IL-6
Ϫ/Ϫ cells. To study whether exogenous IL-6 can restore myotube fusion, IL-6 was added to the medium of IL-6 Ϫ/Ϫ cells during the differentiation process at every other day. IL-6 induced the expression of Socs3 indicating the effectiveness of this treatment (Fig. 6A) . The IL-6 treatment also enhanced the expression of MyHC IIb mRNA on days 1, 2, and 4 of differentiation but failed to increase the expression further on day 6 (Fig. 6B) . Compared with wild-type cells, the MyHC IIb expression levels of IL-6 treated IL-6 Ϫ/Ϫ cells were still significantly reduced on days 4 and 6 (P ϭ 0.001 on day 4; P ϭ 0.01 on day 6). A partial recovery of the impaired fusion of IL-6 Ϫ/Ϫ cells by IL-6 treatment was also observed on day 10 of differentiation after immunostaining for MyHC II protein (Fig.  6C ). IL-6-treated IL-6 Ϫ/Ϫ cells showed a higher fusion index compared with untreated IL-6 Ϫ/Ϫ cells, but it was still reduced compared with wild-type cells.
DISCUSSION
The principal finding of this study is that two components of the IL-6 signaling cascade, IL-6 itself and STAT3, are independently involved in the differentiation and fusion of skeletal muscle cells. shows enhanced phosphorylation of JAK2 and STAT3 as well as increased STAT3 protein levels in differentiating human skeletal muscle cells (30) .
At first sight, IL-6 would be a good candidate for the activation of STAT3 since the knockdown of IL-6 or STAT3 in our study similarly repressed the RNA levels of myogenic markers. Moreover, knockdown of IL-6 previously has been shown to reduce the expression of myogenin in C2C12 cells after 24 h in differentiation medium (3) . However, our study provides evidence for a regulation and function of STAT3 independent of IL-6. This IL-6-independent activation of STAT3 is supported by the following data: Increased expression and secretion of IL-6 are late events during differentiation of C2C12 cells while increased phosphorylation of STAT3 was visible after 6 h in differentiation medium. Knockdown of IL-6 in C2C12 cells did not impair the increased phosphorylation of STAT3 observed during the first 24 h in differentiation medium. In IL-6 Ϫ/Ϫ primary mouse muscle cells, the phosphorylation of STAT3 was not impaired and the STAT3 expression levels during the differentiation were not reduced. These data clearly indicate that in our cell culture system the phosphorylation and signal transduction activity of STAT3 are not dependent on IL-6. Of note, IL-6 was not detectable in the supernatant of IL-6 Ϫ/Ϫ cells grown on Matrigel-coated cell culture dishes.
This raises the question about the mechanism responsible for the activation of STAT3 or more precisely: which mechanism allows or maintains the activity of STAT3 during myogenic differentiation? It should be noted that one explanation for the apparent increase in the tyrosine phosphorylation of STAT3 is the upregulation of STAT3 protein levels during differentiation (31 and data from the present study), which is due to enhanced RNA expression. Importantly, increased STAT3 mRNA levels were found in both C2C12 cells and primary mouse muscle cells 24 h after the start of differentiation with further increases during the later phase. The kinases responsible for the detected tyrosine phosphorylation of STAT3 belong to the Janus family of tyrosine kinases. The data of Wang et al. (31) clearly showed that JAK2 activity is necessary for the phosphorylation and activation of STAT3 during differentiation. JAK2 can be activated by ligands of the IL-6 family of cytokines binding to a gp130/heterodimer receptor complex. In addition, previous work of Spangenburg (24) has highlighted a role for an IGF-I-mediated activation of STAT3 in myogenic differentiation. Spangenburg found that the increased expression and secretion of IGF-I that occurred in differentiating skeletal muscle cells (27) are responsible for the STAT3-mediated Socs3 expression. Moreover, activation of STAT3 by IGF-Imediated IGF-I receptor activation has not only been observed in C2C12 cells but also in mouse muscle tissue in vivo (36) . Based on these findings, we hypothesize that this pathway might also be of importance for the IL-6-independent activation of STAT3 found in the present study. Notably, primary mouse IL-6 Ϫ/Ϫ myoblasts showed similar expression levels of IGF-I as wild-type cells.
A novel pathway described as an activator of the JAK2-STAT3 axis involves the Eph family of receptor tyrosine kinases and their membrane bound ligands, the ephrins (14) . Although there is currently no experimental proof for the hypothesis that ephrin/Eph signals are involved in the activation of STAT3 during differentiation, this idea is intriguing because it opens the possibility that cell-cell contact rather than circulating factors are necessary for the start of myogenic differentiation and would be another explanation for an IL-6-independent activation of STAT3. Notably, the ephrinA/EphA signal has recently been involved in the facilitation of myogenic differentiation by IGF-I (16).
Our data point to an important function of IL-6 for the complete differentiation of muscle cells independent of STAT3 since the fusion of the IL-6 Ϫ/Ϫ muscle cells was clearly disturbed despite the fact that the activation of STAT3 was not different from that in wild-type cells. This function is also independent of Socs3, since the expression level of Socs3 was similar in wild-type and IL-6
Ϫ/Ϫ cells in the later phase of differentiation when the defect in the IL-6
Ϫ/Ϫ cells became evident. The difference in cell fusion could also not be explained by differences in IGF-I expression which is similar in wild-type and IL-6 Ϫ/Ϫ cells at later time points. The spontaneous start of differentiation of the primary myoblasts can also be due to other factors present in the Matrigel that can activate pathways known to promote myogenic differentiation, namely the Akt/PKB, ERK, or p38 MAPK pathway. Reduced activation of these pathways in IL-6 Ϫ/Ϫ cells may also contribute to the impaired differentiation of these cells, since the pathways can also be activated by IL-6 (3, 10, 35) .
Our data clearly indicate that IL-6 is important for the fusion of skeletal muscle cells. In vivo data suggest that IL-6 deficiency could be compensated during development since IL-6 Ϫ/Ϫ mice exhibit no reduced myofiber number or myofiber cross-sectional area in plantaris muscle (23) and MyHC IIb RNA expression was not reduced in adult muscle tissue of these mice as shown in the present study. However, IL-6 might be of relevance when formation of myofibers is necessary in adults after functional muscle overloading or tissue injury. Under these conditions, increased muscular expression of IL-6 is detected in mice and humans as well as phosphorylation of STAT3 particularly in activated satellite cells and proliferating myoblasts (15, 23, 28, 29) . Furthermore, Serrano et al. (23) could show that in IL-6 Ϫ/Ϫ mice the compensatory muscle hypertrophy after overloading is reduced. To conclude, there is good evidence that IL-6 and STAT3 are important for the activation and proliferation of satellite cells and myoblasts during postnatal skeletal muscle growth. By using primary and C2C12 cell culture models for myogenic differentiation, we can now demonstrate that IL-6 also has a crucial function for the differentiation of myoblasts that is not mediated via STAT3.
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